Vitamin D Effect on Plasma Glucose
No significant differences were seen in fasting or 2-hour glucose tolerance test with vitamin D supplementation.
No significant differences were seen in fasting or 2-hour glucose tolerance test with vitamin D supplementation.
Changes in quantity and attenuation of abdominal fat affect changes in incident CVD and metabolic risk factors.
Non-statin therapies reduced cardiovascular risk by 25% for each 1 mmol/L decrease in LDL-C levels.
Statins were recommended less often using ESC guidelines vs AHA/ACC guidelines.
Overall, 92.7% of patients assigned to alirocumab were able to cut their use of lipoprotein apheresis by at least half.
Among patients with heterozygous familial hypercholesterolemia, alirocumab was associated with a 75% reduction in lipoprotein apheresis compared with placebo.
Evolocumab reduced low-density lipoprotein cholesterol by more than 50% in all glycemic status subgroups.
Statin therapy decreased the risk of major vascular events by about one-quarter per mmol/L in LDL-C reduction.
Patients with late-onset asthma were 57% more likely than those with early-onset asthma to suffer from CVD events.
Statin use modified vaccine effectiveness and influenza risk for A(H3N2) infection but not for A(H1N1).